Current and potential inflammation targeted therapies in head and neck cancer

Current Opinion in Pharmacology

Volumn 9, Issue 4, 2009, Pages 389-395

  Wang, Frederick ^a,b   Arun, Pattatheyil ^b   Friedman, Jay ^b   Chen, Zhong ^b   Van Waes, Carter ^b  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATLIZUMAB; BORTEZOMIB; CELECOXIB; CETUXIMAB; CURCUMIN; CYCLOOXYGENASE 2; EPIDERMAL GROWTH FACTOR RECEPTOR; ETANERCEPT; GEFITINIB; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HEAT SHOCK PROTEIN 90 INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INFLIXIMAB; INTERLEUKIN 1ALPHA; INTERLEUKIN 6; INTERLEUKIN 8; JANUS KINASE; KETOROLAC; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; PHOSPHATIDYLINOSITOL 3 KINASE; PROSTAGLANDIN E2; PROSTAGLANDIN SYNTHASE INHIBITOR; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; SCATTER FACTOR; STAT3 PROTEIN; SULINDAC; THALIDOMIDE DERIVATIVE; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; UNINDEXED DRUG; VASCULOTROPIN;

CLINICAL TRIAL; DRUG EFFICACY; DRUG TARGETING; GENE EXPRESSION REGULATION; HEAD AND NECK CARCINOMA; HUMAN; INFLAMMATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TARGETING; REVIEW; SIGNAL TRANSDUCTION; SQUAMOUS CELL CARCINOMA;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTINEOPLASTIC AGENTS; DRUG DELIVERY SYSTEMS; GENE TARGETING; GENE THERAPY; HEAD AND NECK NEOPLASMS; HUMANS; INFLAMMATION; INFLAMMATION MEDIATORS; SIGNAL TRANSDUCTION;

EID: 68849108871     PISSN: 14714892     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.coph.2009.06.005     Document Type: Review

References (50)

1. Jemal A., Siegel R., Ward E., Hao Y., Xu J., Murray T., and Thun M.J. Cancer statistics. CA Cancer J Clin 58 (2008) 71-96
2. Allen C.T., Ricker J.L., Chen Z., and Van Waes C. Role of activated nuclear factor-kappaB in the pathogenesis and therapy of squamous cell carcinoma of the head and neck. Head Neck 29 (2007) 959-971
3. Molinolo A.A., Amornphimoltham P., Squarize C.H., Castilho R.M., Patel V., and Gutkind J.S. Dysregulated molecular networks in head and neck carcinogenesis. Oral Oncol 45 (2009) 324-334. A review highlighting the importance of signal networks in pathogenesis of HNSCC and need for targeting pathways with multiple agents.
4. Serefoglou Z., Yapijakis C., Nkenke E., and Vairaktaris E. Genetic association of cytokine DNA polymorphisms with head and neck cancer. Oral Oncol 44 (2008) 1093-1099
5. Mantovani A., Allavena P., Sica A., and Balkwill F. Cancer-related inflammation. Nature 454 (2008) 436-444
6. Pries R., Nitsch S., and Wollenberg B. Role of cytokines in head and neck squamous cell carcinoma. Expert Rev Anticancer Ther 6 (2006) 1195-1203
7. Lee T.L., Yeh J., Van Waes C., and Chen Z. Epigenetic modification of SOCS-1 differentially regulates STAT3 activation in response to interleukin-6 receptor and epidermal growth factor receptor signaling through JAK and/or MEK in head and neck squamous cell carcinomas. Mol Cancer Ther 5 (2006) 8-19
8. Lee T.L., Yang X.P., Yan B., Friedman J., Duggal P., Bagain L., Dong G., Yeh N.T., Wang J., Zhou J., et al. A novel nuclear factor-kappaB gene signature is differentially expressed in head and neck squamous cell carcinomas in association with TP53 status. Clin Cancer Res 13 (2007) 5680-5691. This is the first study to demonstrate an interaction between TP53 status and activation of NF-κB and proinflammatory and prosurvival genes in HNSCC.
9. Allen C., Duffy S., Teknos T., Islam M., Chen Z., Albert P.S., Wolf G., and Van Waes C. Nuclear factor-kappaB-related serum factors as longitudinal biomarkers of response and survival in advanced oropharyngeal carcinoma. Clin Cancer Res 13 (2007) 3182-3190. Demonstrates proinflammatory cytokines can be used as markers of treatment response and recurrence.
10. Worden B., Yang X.P., Lee T.L., Bagain L., Yeh N.T., Cohen J.G., Van Waes C., and Chen Z. Hepatocyte growth factor/scatter factor differentially regulates expression of proangiogenic factors through Egr-1 in head and neck squamous cell carcinoma. Cancer Res 65 (2005) 7071-7080
11. Kanazawa T., Nishino H., Hasegawa M., Ohta Y., Iino Y., Ichimura K., and Noda Y. Interleukin-6 directly influences proliferation and invasion potential of head and neck cancer cells. Eur Arch Otorhinolaryngol 264 (2007) 815-821
12. Duffy S.A., Taylor J.M., Terrell J.E., Islam M., Li Y., Fowler K.E., Wolf G.T., and Teknos T.N. Interleukin-6 predicts recurrence and survival among head and neck cancer patients. Cancer 113 (2008) 750-757
13. Van Waes C. Nuclear factor-kappaB in development, prevention, and therapy of cancer. Clin Cancer Res 13 (2007) 1076-1082
14. Leeman R.J., Lui V.W., and Grandis J.R. STAT3 as a therapeutic target in head and neck cancer. Expert Opin Biol Ther 6 (2006) 231-241
15. Lee T.L., Yeh J., Friedman J., Yan B., Yang X., Yeh N.T., Van Waes C., and Chen Z. A signal network involving coactivated NF-kappaB and STAT3 and altered p53 modulates BAX/BCL-XL expression and promotes cell survival of head and neck squamous cell carcinomas. Int J Cancer 122 (2008) 1987-1998
16. Brown M., Cohen J., Arun P., Chen Z., and Van Waes C. NF-kappaB in carcinoma therapy and prevention. Expert Opin Ther Targets 12 (2008) 1109-1122
17. Duan J., Friedman J., Nottingham L., Chen Z., Ara G., and Van Waes C. Nuclear factor-kappaB p65 small interfering RNA or proteasome inhibitor bortezomib sensitizes head and neck squamous cell carcinomas to classic histone deacetylase inhibitors and novel histone deacetylase inhibitor PXD101. Mol Cancer Ther 6 (2007) 37-50
18. Allen C., Saigal K., Nottingham L., Arun P., Chen Z., and Van Waes C. Bortezomib-induced apoptosis with limited clinical response is accompanied by inhibition of canonical but not alternative nuclear factor-{kappa}B subunits in head and neck cancer. Clin Cancer Res 14 (2008) 4175-4185
19. Van Waes C., Yu M., Nottingham L., and Karin M. Inhibitor-kappaB kinase in tumor promotion and suppression during progression of squamous cell carcinoma. Clin Cancer Res 13 (2007) 4956-4959
20. Yu M., Yeh J., and Van Waes C. Protein kinase casein kinase 2 mediates inhibitor-kappaB kinase and aberrant nuclear factor-kappaB activation by serum factor(s) in head and neck squamous carcinoma cells. Cancer Res 66 (2006) 6722-6731
21. King K.E., Ponnamperuma R.M., Allen C., Lu H., Duggal P., Chen Z., Van Waes C., and Weinberg W.C. The p53 homologue DeltaNp63alpha interacts with the nuclear factor-kappaB pathway to modulate epithelial cell growth. Cancer Res 68 (2008) 5122-5131. First paper to demonstrate a novel transcription factor formed by member of TP53 and NF-κB family, which modulates cell growth (and cytokine expression).
22. Gurova K.V., Hill J.E., Guo C., Prokvolit A., Burdelya L.G., Samoylova E., Khodyakova A.V., Ganapathi R., Ganapathi M., Tararova N.D., Bosykh D., et al. Small molecules that reactivate p53 in renal cell carcinoma reveal a NF-kappaB-dependent mechanism of p53 suppression in tumors. Proc Natl Acad Sci U S A 102 (2005) 17448-17453
23. Friedman J., Nottingham L., Duggal P., Pernas F.G., Yan B., Yang X.P., Chen Z., and Van Waes C. Deficient TP53 expression, function, and cisplatin sensitivity are restored by quinacrine in head and neck cancer. Clin Cancer Res 13 (2007) 6568-6578
24. Rasheed M.H., Beevi S.S., and Geetha A. Enhanced lipid peroxidation and nitric oxide products with deranged antioxidant status in patients with head and neck squamous cell carcinoma. Oral Oncol 43 (2007) 333-338
25. Sablina A.A., Budanov A.V., Ilyinskaya G.V., Agapova L.S., Kravchenko J.E., and Chumakov P.M. The antioxidant function of the p53 tumor suppressor. Nat Med 11 (2005) 1306-1313
26. Zhang Q.S., Eaton L., Snyder E.R., Houghtaling S., Mitchell J.B., Finegold M., Van Waes C., and Grompe M. Tempol protects against oxidative damage and delays epithelial tumor onset in Fanconi anemia mice. Cancer Res 68 (2008) 1601-1608
27. Pernas F.G., Allen C.T., Winters M.E., Dabir B., Saigal K., Mundinger G.S., Yan B., Friedman J., Xu X., Morris J.C., et al. Proteomic signatures and responses of epitermal growth factor receptor and survival signal pathways correspond to gefitinib sensitivity in head and neck cancer. Clin Cancer Res 15 (2009) 2361-2372
28. Ricker J.L., Chen Z., Yang X.P., Pribluda V.S., Swartz G.M., and Van Waes C. 2-methoxyestradiol inhibits hypoxia-inducible factor 1alpha, tumor growth, and angiogenesis and augments paclitaxel efficacy in head and neck squamous cell carcinoma. Clin Cancer Res 10 (2004) 8665-8673
29. Amornphimoltham P., Patel V., Sodhi A., Nikitakis N.G., Sauk J.J., Sausville E.A., Molinolo A.A., and Gutkind J.S. Mammalian target of rapamycin, a molecular target in squamous cell carcinomas of the head and neck. Cancer Res 65 (2005) 9953-9961
30. Nathan C.O., Amirghahari N., Rong X., Giordano T., Sibley D., Nordberg M., Glass J., Agarwal A., and Caldito G. Mammalian target of rapamycin inhibitors as possible adjuvant therapy for microscopic residual disease in head and neck squamous cell cancer. Cancer Res 67 (2007) 2160-2168
31. Van Waes C, Allen C, Citrin D, Colevas AD, Harold N, Rudy S, Muir C, Chen Z, Singh AK, Albert P, et al.: Molecular and clinical responses in a Phase I study of gefitinib combined with paclitaxel and radiation in patients with locally advanced head and neck cancers. Int J Rad Oncol Biol Phys 2009, in press.
32. Camacho M., Leon X., Fernandez-Figueras M.T., Quer M., and Vila L. Prostaglandin E(2) pathway in head and neck squamous cell carcinoma. Head Neck 30 (2008) 1175-1181
33. Egberts J.H., Cloosters V., Noack A., Schniewind B., Thon L., Klose S., Kettler B., von Forstner C., Kneitz C., Tepel J., Adam D., et al. Anti-tumor necrosis factor therapy inhibits pancreatic tumor growth and metastasis. Cancer Res 68 (2008) 1443-1450. Demonstrates potential of inhibition of TNF, a cytokine activator of NF-κB, in pancreatic cancer.
34. Zidi I, Mestiri S, Bartegi A, Amor NB: TNF-alpha and its inhibitors in cancer. Med Oncol 2009, in press.
35. Nishimoto N., and Kishimoto T. Interleukin 6: from bench to bedside. Nat Clin Pract Rheumatol 2 (2006) 619-626
36. Chen Z., Ricker J.L., Malhotra P.S., Nottingham L., Bagain L., Lee T.L., Yeh N.T., and Van Waes C. Differential bortezomib sensitivity in head and neck cancer lines corresponds to proteasome, nuclear factor-kappaB and activator protein-1 related mechanisms. Mol Cancer Ther 7 (2008) 1949-1960. Demonstrates limited activity of proteasome inhibition in patients may be explained by alternative NF-κB as well as STAT3 and MAPK activation.
37. National Cancer Institute. Phase I study of bortezomib and cetuximab without or with cisplatin in combination with radiation therapy for advanced head and neck cancer. ClinicalTrials.gov [Internet] (2007), National Library of Medicine (US), Bethesda (MD). http://clinicaltrials.gov/ct2/show/NCT00629226 [cited 2009 February 19]. Available from: http://clinicaltrials.gov/ct2/show/NCT00629226 NLM Identifier: NCT00629226
38. Messaoudi S., Peyrat J.F., Brion J.D., and Alami M. Recent advances in Hsp90 inhibitors as antitumor agents. Anticancer Agents Med Chem 8 (2008) 761-782
39. Aggarwal S., Takada Y., Singh S., Myers J.N., and Aggarwal B.B. Inhibition of growth and survival of human head and neck squamous cell carcinoma cells by curcumin via modulation of nuclear factor-kappaB signaling. Int J Cancer 111 (2004) 679-692
40. Sharma R.A., Euden S.A., Platton S.L., Cooke D.N., Shafayat A., Hewitt H.R., Marczylo T.H., Morgan B., Hemingway D., Plummer S.M., et al. Phase I clinical trial of oral curcumin: biomarkers of systemic activity and compliance. Clin Cancer Res 10 (2004) 6847-6854
41. Dhillon N., Aggarwal B.B., Newman R.A., Wolff R.A., Kunnumakkara A.B., Abbruzzese J.L., Ng C.S., Badmaev V., and Kurzrock R. Phase II trial of curcumin in patients with advanced pancreatic cancer. Clin Cancer Res 14 (2008) 4491-4499. Trial demonstrates activity of curcumin in pancreatic carcinoma, and inhibitor of NF-κB, despite poor bioavailability.
42. Anand P., Sundaram C., Jhurani S., Kunnumakkara A.B., and Aggarwal B.B. Curcumin and cancer: an 'old-age' disease with an 'age-old' solution. Cancer Lett 267 (2008) 133-164
43. Dan H.C., and Baldwin A.S. Differential involvement of IkappaB kinases alpha and beta in cytokine- and insulin-induced mammalian target of rapamycin activation determined by Akt. J Immunol 180 (2008) 7582-7589
44. Czerninski R., Amornphimoltham P., Patel V., Molinolo A.A., and Gutkind J.S. Targeting mammalian target of rapamycin by rapamycin prevents tumor progression in an oral-specific chemical carcinogenesis model. Cancer Prev Res (Phila Pa) 2 (2009) 27-36. Demonstrates potential of mTOR inhibitors that block translation of inflammatory and angiogenesis factors to inhibit HNSCC.
45. Loeffler-Ragg J., Schwentner I., Sprinzl G.M., and Zwierzina H. EGFR inhibition as a therapy for head and neck squamous cell carcinoma. Expert Opin Investig Drugs 17 (2008) 1517-1531
46. Sen M., Tosca P.J., Zwayer C., Ryan M.J., Johnson J.D., Knostman K.A., Giclas P.C., Peggins J.O., Tomaszewski J.E., McMurray T.P., et al. Lack of toxicity of a STAT3 decoy oligonucleotide. Cancer Chemother Pharmacol 63 (2009) 983-995. A novel oligonucleotide-based inhibitor of STAT3 in clinical trial.
47. Lin D.T., Subbaramaiah K., Shah J.P., Dannenberg A.J., and Boyle J.O. Cyclooxygenase-2: a novel molecular target for the prevention and treatment of head and neck cancer. Head Neck 24 (2002) 792-799
48. Mulshine J.L., Atkinson J.C., Greer R.O., Papadimitrakopoulou V.A., Van Waes C., Rudy S., Martin J.W., Steinberg S.M., Liewehr D.J., Avis I., et al. Randomized, double-blind, placebo-controlled Phase IIb trial of the cyclooxygenase inhibitor ketorolac as an oral rinse in oropharyngeal leukoplakia. Clin Cancer Res 10 (2004) 1565-1573. A negative controlled study regarding activity of COX inhibitors as an oral rinse.
49. Papadimitrakopoulou V.A., William Jr. W.N., Dannenberg A.J., Lippman S.M., Lee J.J., Ondrey F.G., Peterson D.E., Feng L., Atwell A., El-Naggar A.K., et al. Pilot randomized Phase II study of celecoxib in oral premalignant lesions. Clin Cancer Res 14 (2008) 2095-2101
50. Centre Hospitalier Universitaire Vaudois. Celecoxib in treating patients with head and neck cancer that can be removed by surgery. ClinicalTrials.gov [Internet] (2006), National Library of Medicine (US), Bethesda (MD). http://clinicaltrials.gov/ct2/show/NCT00357617 [cited 2009 February 19]. Available from: http://clinicaltrials.gov/ct2/show/NCT00357617 NLM Identifier: NCT00357617